D. D. and V. Hoff, There are no bad anticancer agents, only bad clinical trial designs-twenty-first Richard and Hinda Rosenthal foundation award lecture, Clinical Cancer Research, vol.4, issue.5, pp.1079-1086, 1998.

R. Mick, J. J. Crowley, and R. J. Carroll, Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint, Controlled Clinical Trials, vol.21, issue.4, pp.343-359, 2000.

D. D. Hoff, J. J. Stephenson, and P. Rosen, Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers, Journal of Clinical Oncology, vol.28, issue.33, pp.4877-4883, 2010.

C. Massard, S. Michiels, and C. Ferté, High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial, Cancer Discovery, vol.7, issue.6, pp.586-595, 2017.

M. Schwaederle, B. A. Parker, and R. B. Schwab, Precision oncology: The UC San Diego moores cancer center predict experience, Molecular Cancer Therapeutics, vol.15, issue.4, pp.743-752, 2016.

A. Bonetti, M. Zaninelli, and R. Leone, Use of the ratio of time to progression following first-and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma, Annals of Oncology, vol.12, issue.2, pp.187-191, 2001.

L. Belin, M. Kamal, and C. Mauborgne, Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: Cross-over analysis from the SHIVA trial, Annals of Oncology, vol.28, pp.592-596, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01791290

M. Ducreux, D. Malka, and J. Mendiboure, Sequential versus combination chemotherapy for the treatment of advanced 8 Computational and Mathematical Methods in Medicine colorectal cancer (FFCD 2000-05): An open-label, randomised, phase 3 trial, The Lancet Oncology, vol.12, issue.11, pp.1032-1044, 2011.

J. Pénichoux, S. Michiels, and O. Bouché, Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial, European Journal of Cancer, vol.49, issue.8, pp.1882-1888, 2013.

L. Duchateau and P. Janssen, The frailty model, 2008.
URL : https://hal.archives-ouvertes.fr/hal-01602399

M. Munda, F. Rotolo, and C. Legrand, parfm: parametric frailty models in R, Journal of Statistical Software, vol.51, issue.11, 2012.

S. Kovalchik and W. Mietlowski, Statistical methods for a phase II oncology trial with a growth modulation index (GMI) endpoint, Contemporary Clinical Trials, vol.32, issue.1, pp.99-107, 2011.

A. Dufresne, X. Pivot, and C. Tournigand, Impact of chemotherapy beyond the first line in patients with metastatic breast cancer, Breast Cancer Research and Treatment, vol.107, issue.2, pp.275-279, 2008.

M. G. Hudgens and G. A. Satten, Midrank unification of rank tests for exact, tied, and censored data, Journal of Nonparametric Statistics, vol.14, issue.5, pp.569-581, 2002.

W. J. Owen, A power analysis of tests for paired lifetime data, Lifetime Data Analysis, vol.11, issue.2, pp.233-243, 2005.

E. M. Agency, Guideline on the evaluation of anticancer medicinal products in man, European Medicines Agency, vol.44, p.33, 2012.

N. Penel, G. D. Demetri, and J. Y. Blay, Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy, Annals of Oncology, vol.24, issue.2, pp.537-542, 2013.

S. Bhattacharya, G. Fyfe, R. J. Gray, and D. J. Sargent, Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials, Journal of Clinical Oncology, vol.27, issue.35, pp.5958-5964, 2009.

K. S. Panageas, L. Ben-porat, M. N. Dickler, P. B. Chapman, and D. Schrag, When you look matters: The effect of assessment schedule on progression-free survival, Journal of the National Cancer Institute, vol.99, issue.6, pp.428-432, 2007.